mazdutide vs Zabopegdutide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline

mazdutide

Marketed by Innovent Biologics under a licence from Eli Lilly

Phase 3 in Obesitypeptide
Reliable signal

NCT05607680 · Phase 3 · completed

GLORY-1 was a randomized, double-blind, placebo-controlled Phase 3 trial in China. It assigned 610 adults with obesity or overweight to mazdutide 4 mg, mazdutide 6 mg or placebo once weekly. The two primary endpoints at week 32 were the percent change in body weight and the proportion of participants who lost at least 5% of their body weight. Both doses were significantly better than placebo on both endpoints (P<0.001 for all comparisons), so the trial met its primary endpoints. The figures come from the peer-reviewed paper in the New England Journal of Medicine.

Next expected readout: December 2026 · NCT06884293 (registry estimate)

Reported efficacy

Co-primary: percent change in body weight from baseline to week 32, and proportion of participants with at least 5% body-weight reduction at week 32: Co-primary 1, percent change in body weight from baseline to week 32 (treatment-policy estimand): mazdutide 4 mg -10.09% (95% CI -11.15 to -9.04), 6 mg -12.55% (95% CI -13.64 to -11.45) vs placebo +0.45% (95% CI -0.61 to 1.52); P<0.001 for both doses vs placebo, met. Co-primary 2, weight reduction of at least 5% at week 32: 73.9% (4 mg) and 82.0% (6 mg) vs 10.5% (placebo); P<0.001 for both doses vs placebo, met. (met)

Result source: NCT05607680

Zabopegdutide

Developed by D&D Pharmatech and partners

Phase 2 in Obesitypeptide
Partial signal

NCT04812262 · Phase 1 · completed

This Phase 1 study randomized overweight or obese adults with type 2 diabetes and fatty liver disease to DD01 or placebo in sequential single and multiple ascending-dose cohorts, with quadruple blinding and 255 participants in total. All of its registered primary endpoints measured safety and tolerability, so the trial made no formal efficacy test, and no results were posted on the registry. The sponsor announced a reduction in liver fat measured by MRI-PDFF in the high-dose group (p < 0.0001 versus placebo), but that outcome was not a registered primary endpoint and the figure comes from a company press release.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Number of participants with treatment-related adverse events and serious adverse events (Part A - 43 days); Number of participants with treatment-related adverse events and serious adverse events (TEAEs) (Part B - 57 days); Number of participants with clinically significant abnormalities in clinical laboratory values (Part A - 43 days); Number of participants with clinically significant abnormalities in clinical laboratory values (Part B - 57 days); Number of participants with clinically significant abnormalities in physical examinations (Part A - 43 days); Number of participants with clinically significant abnormalities in physical examinations (Part B - 57 days); Number of participants with clinically significant abnormalities in vital signs (Part A - 43 days); Number of participants with clinically significant abnormalities in vital signs (Part B - 57 days); Blood Pressure assessed by 24-hour ambulatory blood pressure monitoring (ABPM) (Part A - 43 days); Blood Pressure assessed by 24-hour ambulatory blood pressure monitoring (ABPM) (Part B - 57 days); Heart Rate assessed by 24-hour ambulatory electrocardiography monitoring reader) (Part A - 43 days); Heart Rate assessed by 24-hour ambulatory electrocardiography monitoring reader) (Part B - 57 days); Number of participants with clinically significant abnormalities in 12-lead ECGs (Part A - 43 days); Number of participants with clinically significant abnormalities in 12-lead ECGs (Part B - 57 days): Randomized, double-blind, placebo-controlled single and multiple ascending dose study at four US clinical sites: following only 4 weeks of treatment, all subjects in the high dose group achieved at least a 40% reduction in liver fat, with a mean reduction of more than 50% measured by MRI-PDFF (p < 0.0001 versus placebo). (not_applicable)

Result source: NCT04812262

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointmazdutideZabopegdutide
Body weight, % change-7.3% vs -0.8%−6.5 vs placebo3/6 mg · wk 32 · n 32NCT06124807
7 other results
  • -18.1% vs -0.8% 16 mg · wk 32 · n 51 · Phase 2 · primary NCT06124807
  • -15.6% vs -0.8% 10 mg · wk 32 · n 48 · Phase 2 · primary NCT06124807
  • -10.5% vs -0.0% 3/6 mg · wk 48 · n 32 · Phase 2 · secondary NCT06124807
  • -22.3% vs -0.0% 16 mg · wk 48 · n 51 · Phase 2 · secondary NCT06124807
  • -19.2% vs -0.0% 10 mg · wk 48 · n 48 · Phase 2 · secondary NCT06124807
  • -12.6% vs 0.5% mazdutide 6mg · wk 32 · Phase 3 · primary NCT05607680
  • -10.1% vs 0.5% mazdutide 4mg · wk 32 · Phase 3 · primary NCT05607680
—Not reported
Weight loss of 5% or more74.8% vs 26.0%+48.8 vs placebo3/6 mg · wk 48 · n 32NCT06124807
5 other results
  • 67.6% vs 24.0% 3/6 mg · wk 32 · n 32 · Phase 2 · secondary NCT06124807
  • 91.9% vs 26.0% 16 mg · wk 48 · n 51 · Phase 2 · secondary NCT06124807
  • 92.2% vs 24.0% 16 mg · wk 32 · n 51 · Phase 2 · secondary NCT06124807
  • 95.9% vs 26.0% 10 mg · wk 48 · n 48 · Phase 2 · secondary NCT06124807
  • 96.1% vs 24.0% 10 mg · wk 32 · n 48 · Phase 2 · secondary NCT06124807
—Not reported
Weight loss of 10% or more57.9% vs 13.8%+44.1 vs placebo3/6 mg · wk 48 · n 32NCT06124807
5 other results
  • 45.4% vs 8.7% 3/6 mg · wk 32 · n 32 · Phase 2 · secondary NCT06124807
  • 80.7% vs 13.8% 16 mg · wk 48 · n 51 · Phase 2 · secondary NCT06124807
  • 77.1% vs 8.7% 16 mg · wk 32 · n 51 · Phase 2 · secondary NCT06124807
  • 84.0% vs 13.8% 10 mg · wk 48 · n 48 · Phase 2 · secondary NCT06124807
  • 86.0% vs 8.7% 10 mg · wk 32 · n 48 · Phase 2 · secondary NCT06124807
—Not reported
Waist circumference, change (cm)—Not posted · NCT05607680—Not reported

Body weight, % change

mazdutide
-7.3% vs -0.8%−6.5 vs placebo3/6 mg · wk 32 · n 32NCT06124807
7 other results
  • -18.1% vs -0.8% 16 mg · wk 32 · n 51 · Phase 2 · primary NCT06124807
  • -15.6% vs -0.8% 10 mg · wk 32 · n 48 · Phase 2 · primary NCT06124807
  • -10.5% vs -0.0% 3/6 mg · wk 48 · n 32 · Phase 2 · secondary NCT06124807
  • -22.3% vs -0.0% 16 mg · wk 48 · n 51 · Phase 2 · secondary NCT06124807
  • -19.2% vs -0.0% 10 mg · wk 48 · n 48 · Phase 2 · secondary NCT06124807
  • -12.6% vs 0.5% mazdutide 6mg · wk 32 · Phase 3 · primary NCT05607680
  • -10.1% vs 0.5% mazdutide 4mg · wk 32 · Phase 3 · primary NCT05607680
Zabopegdutide
—Not reported

Weight loss of 5% or more

mazdutide
74.8% vs 26.0%+48.8 vs placebo3/6 mg · wk 48 · n 32NCT06124807
5 other results
  • 67.6% vs 24.0% 3/6 mg · wk 32 · n 32 · Phase 2 · secondary NCT06124807
  • 91.9% vs 26.0% 16 mg · wk 48 · n 51 · Phase 2 · secondary NCT06124807
  • 92.2% vs 24.0% 16 mg · wk 32 · n 51 · Phase 2 · secondary NCT06124807
  • 95.9% vs 26.0% 10 mg · wk 48 · n 48 · Phase 2 · secondary NCT06124807
  • 96.1% vs 24.0% 10 mg · wk 32 · n 48 · Phase 2 · secondary NCT06124807
Zabopegdutide
—Not reported

Weight loss of 10% or more

mazdutide
57.9% vs 13.8%+44.1 vs placebo3/6 mg · wk 48 · n 32NCT06124807
5 other results
  • 45.4% vs 8.7% 3/6 mg · wk 32 · n 32 · Phase 2 · secondary NCT06124807
  • 80.7% vs 13.8% 16 mg · wk 48 · n 51 · Phase 2 · secondary NCT06124807
  • 77.1% vs 8.7% 16 mg · wk 32 · n 51 · Phase 2 · secondary NCT06124807
  • 84.0% vs 13.8% 10 mg · wk 48 · n 48 · Phase 2 · secondary NCT06124807
  • 86.0% vs 8.7% 10 mg · wk 32 · n 48 · Phase 2 · secondary NCT06124807
Zabopegdutide
—Not reported

Waist circumference, change (cm)

mazdutide
—Not posted · NCT05607680
Zabopegdutide
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Zabopegdutide: no structured comparison results are available for Obesity.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. mazdutide: 4 of 4 rows · Zabopegdutide: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricmazdutide
Dropout rate
12.5%3/6 mga
NCT06124807 · Phase 2 · registry result, not featured evidence
show 2 more results
33.3%16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
22.9%10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0%3/6 mga
NCT06124807 · Phase 2 · registry result, not featured evidence
show 2 more results
9.8%16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
4.2%10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
Serious AEs
3.1%3/6 mga
NCT06124807 · Phase 2 · registry result, not featured evidence
show 2 more results
3.9%16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
2.1%10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
3/6 mga
nausea 43.8% (placebo 25.5%)
diarrhoea 28.1% (placebo 12.8%)
constipation 21.9% (placebo 10.6%)
NCT06124807 · Phase 2 · registry result, not featured evidence
show 2 more results
16 mg
nausea 66.7% (placebo 25.5%)
vomiting 47.1% (placebo 2.1%)
constipation 37.3% (placebo 10.6%)
NCT06124807 · Phase 2 · registry result, not featured evidence
10 mg
nausea 46.8% (placebo 25.5%)
constipation 29.8% (placebo 10.6%)
diarrhoea 25.5% (placebo 12.8%)
NCT06124807 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

mazdutide

Weight -7.33% (n=32) vs -0.85% (n=48) placebo @ 32wk3/6 mg
percent change · % of baseline
NCT06124807 · Phase 2 · registry result, not featured evidence
show 7 more results
-10.54% (n=32) vs -0.047% (n=48) placebo @ 48wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-12.55% vs 0.45% placebo @ 32wkmazdutide 6mg
NCT05607680 · Phase 3 · sponsor-reported, not registry data
-10.09% vs 0.45% placebo @ 32wkmazdutide 4mg
NCT05607680 · Phase 3 · sponsor-reported, not registry data
-18.1% (n=51) vs -0.85% (n=48) placebo @ 32wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-22.3% (n=51) vs -0.047% (n=48) placebo @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-15.6% (n=48) vs -0.85% (n=48) placebo @ 32wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-19.2% (n=48) vs -0.047% (n=48) placebo @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
Weight -7.79 vs -0.98 placebo kg @ 32wk3/6 mg
absolute change · kg
NCT06124807 · Phase 2 · registry result, not featured evidence
show 5 more results
-11.15 vs -0.15 placebo kg @ 48wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-19.2 vs -0.98 placebo kg @ 32wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-23.9 vs -0.15 placebo kg @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-16.1 vs -0.98 placebo kg @ 32wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-19.7 vs -0.15 placebo kg @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
Weight Loss 5% 67.64% (n=32) vs 23.97% (n=48) placebo @ 32wk3/6 mg
responder rate · % of participants
NCT06124807 · Phase 2 · registry result, not featured evidence
show 5 more results
74.77% (n=32) vs 25.96% (n=48) placebo @ 48wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
92.23% (n=51) vs 23.97% (n=48) placebo @ 32wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
91.9% (n=51) vs 25.96% (n=48) placebo @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
96.1% (n=48) vs 23.97% (n=48) placebo @ 32wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
95.91% (n=48) vs 25.96% (n=48) placebo @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
Weight Loss 10% 45.43% (n=32) vs 8.73% (n=48) placebo @ 32wk3/6 mg
responder rate · % of participants
NCT06124807 · Phase 2 · registry result, not featured evidence
show 5 more results
57.86% (n=32) vs 13.77% (n=48) placebo @ 48wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
77.08% (n=51) vs 8.73% (n=48) placebo @ 32wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
80.73% (n=51) vs 13.77% (n=48) placebo @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
85.95% (n=48) vs 8.73% (n=48) placebo @ 32wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
83.97% (n=48) vs 13.77% (n=48) placebo @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
BMI -2.84 vs -0.32 placebo kg @ 32wk3/6 mg
absolute change · kg
NCT06124807 · Phase 2 · registry result, not featured evidence
show 5 more results
-4.07 vs -0.017 placebo kg @ 48wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-6.86 vs -0.32 placebo kg @ 32wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-8.53 vs -0.017 placebo kg @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-5.81 vs -0.32 placebo kg @ 32wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-7.15 vs -0.017 placebo kg @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
Liver Fat -6.15% (n=22) vs -1.62% (n=36) placebo @ 32wk3/6 mg
absolute change · percentage points
NCT06124807 · Phase 2 · registry result, not featured evidence
show 11 more results
-7.81% (n=22) vs -1.35% (n=36) placebo @ 48wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-9.3% (n=11) vs -4.3% (n=19) placebo @ 32wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-12.4% (n=11) vs -4.6% (n=19) placebo @ 48wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-7.91% (n=31) vs -1.62% (n=36) placebo @ 32wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-7.74% (n=31) vs -1.35% (n=36) placebo @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-12.8% (n=18) vs -4.3% (n=19) placebo @ 32wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-12.6% (n=18) vs -4.6% (n=19) placebo @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-7.78% (n=33) vs -1.62% (n=36) placebo @ 32wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-8.07% (n=33) vs -1.35% (n=36) placebo @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-13.8% (n=19) vs -4.3% (n=19) placebo @ 32wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-13.9% (n=19) vs -4.6% (n=19) placebo @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
Liver PDFF -53.5% (n=22) vs -14.1% (n=36) placebo @ 32wk3/6 mg
percent change · % of baseline
NCT06124807 · Phase 2 · registry result, not featured evidence
show 11 more results
-68% (n=22) vs -11.7% (n=36) placebo @ 48wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-53.4% (n=11) vs -24.7% (n=19) placebo @ 32wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-71.2% (n=11) vs -26.3% (n=19) placebo @ 48wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-68.8% (n=31) vs -14.1% (n=36) placebo @ 32wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-67.4% (n=31) vs -11.7% (n=36) placebo @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-73.6% (n=18) vs -24.7% (n=19) placebo @ 32wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-72.3% (n=18) vs -26.3% (n=19) placebo @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-67.7% (n=33) vs -14.1% (n=36) placebo @ 32wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-70.2% (n=33) vs -11.7% (n=36) placebo @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-79.5% (n=19) vs -24.7% (n=19) placebo @ 32wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-80.2% (n=19) vs -26.3% (n=19) placebo @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
MRI-PDFF ≥30% 73.97% (n=22) vs 24.93% (n=36) placebo @ 32wk3/6 mg
responder rate · % of participants
NCT06124807 · Phase 2 · registry result, not featured evidence
show 11 more results
87.73% (n=22) vs 30.04% (n=36) placebo @ 48wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
71.95% (n=11) vs 38.57% (n=19) placebo @ 32wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
86.64% (n=11) vs 36.82% (n=19) placebo @ 48wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
83.4% (n=31) vs 24.93% (n=36) placebo @ 32wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
84.23% (n=31) vs 30.04% (n=36) placebo @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
92.04% (n=18) vs 38.57% (n=19) placebo @ 32wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
78.36% (n=18) vs 36.82% (n=19) placebo @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
84.93% (n=33) vs 24.93% (n=36) placebo @ 32wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
85.7% (n=33) vs 30.04% (n=36) placebo @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
99.71% (n=19) vs 38.57% (n=19) placebo @ 32wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
90.46% (n=19) vs 36.82% (n=19) placebo @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: mazdutide's landscape · Zabopegdutide's landscape